RQ 00310941

Drug Profile

RQ 00310941

Alternative Names: 5-HT 2B antagonist - RaQualia

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer Japan
  • Developer RaQualia Pharma
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Irritable bowel syndrome

Most Recent Events

  • 29 Jan 2018 RaQualia Pharma and ZTE Coming Biotech agree to co-promote and co-develop RQ 00310941 in China
  • 20 Apr 2016 RaQualia receives patent allowance for 5-HT2B in South Korea
  • 22 Feb 2016 Phase-I clinical trials in Irritable bowel syndrome (In healthy volunteers) in United Kingdom (unspecified route) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top